>183,963187,421Goodwill
61,55461,587Intangibles and other assets, net
53,29553,300
Total assets
$690,808$687,015LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:
Current portion of long-term debt
$4,000$4,000
Accounts payable, trade and other
29,90432,640
Other current liabilities
51,30971,609
Total current liabilities
85,213108,249Long-term debt
152,000148,000Other long-term liabilities
38,04837,558
Total liabilities
275,261293,807
Total stockholders' equity
415,547393,208
Total liabilities and stockholders' equity
$690,808$687,015Additional InformationNet debt is a supplemental financial measure that is not required by, or presented in accordance with, USGAAP. The Company believes net debt is helpful in analyzing leverage and as a performance measure for purposes of presentation in this release. The Company defines net debt as total long-term debt (including any current portion) less cash and cash equivalents.
'/>"/>SOURCE Innophos Holdings, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Innophos to Present at 2010 Oppenheimer Industrials Conference2.
China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit3.
Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology4.
China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%5.
China Pharma Holdings, Inc. Appoints The Ruth Group6.
BioAuthorize Holdings, Inc. Names New Directors and Executive and Unveils Modification to Its Voice Biometric Authentication Service7.
China Pharma Holdings, Inc. to Present at Two Upcoming U.S. Investor Conferences8.
China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules9.
China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan10.
JAG Media Holdings, Inc. Announces Letter of Intent for the Acquisition of CardioGenics Inc. by a Wholly-Owned Subsidiary of JAG Media11.
EFT BioTech Holdings, Inc.s Subsidiary Receives First Permit to Cross Taiwan Strait